Interestingly, ILCs, particularly ILC3s, in the inflammatory or tumor microenvironment of patients with IBD or CRC expressed significantly higher levels of CTNNB1, and Wnt/β-catenin downstream genes TCF7, VEGFA and MYC, as compared with control tissues (Fig. 1a). This evidence concerns the gene MYC and inflammatory bowel disease.